Review



antibodies against human mgmt  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems antibodies against human mgmt
    Antibodies Against Human Mgmt, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/Human+MGMT+Antibody/pmc06643039-332-26-30
    Average 92 stars, based on 3 article reviews
    antibodies against human mgmt - by Bioz Stars, 2026-08
    92/100 stars

    Images



    Similar Products

    93
    Santa Cruz Biotechnology mouse monoclonals against human mgmt
    High <t>MGMT</t> protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) <t>and</t> <t>β-actin</t> (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).
    Mouse Monoclonals Against Human Mgmt, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/MGMT+Antibody/pmc08584761-166-4-9
    Average 93 stars, based on 1 article reviews
    mouse monoclonals against human mgmt - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    90
    Millipore monoclonal mouse anti-human antibody against mgmt
    High <t>MGMT</t> protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) <t>and</t> <t>β-actin</t> (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).
    Monoclonal Mouse Anti Human Antibody Against Mgmt, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/monoclonal+mgmt+antibody/10__1002_slash_14651858__cd013316__pub2-2129-2-10
    Average 90 stars, based on 1 article reviews
    monoclonal mouse anti-human antibody against mgmt - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Millipore monoclonal mouse anti-human antibody against mgmt mab16200
    High <t>MGMT</t> protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) <t>and</t> <t>β-actin</t> (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).
    Monoclonal Mouse Anti Human Antibody Against Mgmt Mab16200, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/monoclonal+mgmt+antibody/10__1002_slash_14651858__cd013316__pub2-2129-0-10
    Average 90 stars, based on 1 article reviews
    monoclonal mouse anti-human antibody against mgmt mab16200 - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    92
    R&D Systems antibodies against human mgmt
    High <t>MGMT</t> protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) <t>and</t> <t>β-actin</t> (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).
    Antibodies Against Human Mgmt, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/Human+MGMT+Antibody/pmc06643039-332-26-30
    Average 92 stars, based on 1 article reviews
    antibodies against human mgmt - by Bioz Stars, 2026-08
    92/100 stars
      Buy from Supplier

    90
    Millipore monoclonal mouse anti-human antibody against mgmt clone mt3.1
    Patients’ features.
    Monoclonal Mouse Anti Human Antibody Against Mgmt Clone Mt3.1, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/monoclonal+mgmt+antibody/pmc06466220-128-35-44
    Average 90 stars, based on 1 article reviews
    monoclonal mouse anti-human antibody against mgmt clone mt3.1 - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    OriGene mouse against human mgmt antibody
    Patients’ features.
    Mouse Against Human Mgmt Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+against+human+mgmt/mouse+against+human+mgmt+antibody/pmc04723787-52-7-12
    Average 90 stars, based on 1 article reviews
    mouse against human mgmt antibody - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    High MGMT protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) and β-actin (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).

    Journal: International Journal of Molecular Sciences

    Article Title: Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells

    doi: 10.3390/ijms222111938

    Figure Lengend Snippet: High MGMT protein expression does not account for TMZ resistance in the U373/U373-R isogenic human glioblastoma model. ( a ) O6-methylguanine DNA methyltransferase (MGMT) and β-actin (loading control) protein expression as determined by Western blotting in U373 and U373-R glioblastoma cells in the absence of TMZ, with pictures on the left and quantification on the right ( n = 4). ( b ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of MGMT inhibitor O6-benzylguanine (O6BG). Displayed are the plating efficiency of the vehicle-treated cells at 72 h (left; n = 6); and the surviving fraction (right; n = 6–12), where the data are normalized to the number of corresponding vehicle-treated cells. ( c ) Number of cells 72 h after treatment with the indicated concentrations of TMZ in combination with 50 µM O6BG (O6BG50; left; n = 4) or 100 µM O6BG (O6BG100; right; n = 4). ( d ) Clonogenic assays of the cells that were pretreated for 72 h with increasing concentrations of TMZ and O6BG. Displayed are the plating efficiency of the cells that were treated ± O6BG (left; n = 6); and the surviving fractions of the cells that received O6BG50 (middle; n = 6) or O6BG100 (right; n = 5–6), where the data are normalized to the number of corresponding vehicle-treated cells. All data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, ns: p > 0.05 versus the corresponding control; ### p < 0.005 for whole curve comparison; by Student’s t -test ( a , b left), two-way ANOVA with Sidak’s post hoc test ( b right, c , d middle, d right), or one-way ANOVA with Dunnett’s post hoc test ( d left).

    Article Snippet: The primary antibodies were mouse monoclonals against human MGMT (Santa Cruz Biotechnology, Heidelberg, Germany; catalogue #sc-56157) and against β-actin (Sigma-Aldrich; catalogue #A5441).

    Techniques: Expressing, Western Blot

    Patients’ features.

    Journal: Bioengineering

    Article Title: Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

    doi: 10.3390/bioengineering6010011

    Figure Lengend Snippet: Patients’ features.

    Article Snippet: After blocking of endogenous peroxidase with 3% H 2 O 2 , the sections were pre-treated in an oven with EnVision Flex TRS buffer and immunostained on a DAKO Cytomation autostainer (DAKO, Glostrup, Denmark), using monoclonal mouse anti-human antibody against MGMT (clone MT3.1, MAB16200 EMD Millipore TM , Billerica, MA, USA).

    Techniques: Expressing

    Univariate analysis with Fisher exact test (binomial confidence interval) and multivariate analysis with multiple regression. *: statistically significant.

    Journal: Bioengineering

    Article Title: Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

    doi: 10.3390/bioengineering6010011

    Figure Lengend Snippet: Univariate analysis with Fisher exact test (binomial confidence interval) and multivariate analysis with multiple regression. *: statistically significant.

    Article Snippet: After blocking of endogenous peroxidase with 3% H 2 O 2 , the sections were pre-treated in an oven with EnVision Flex TRS buffer and immunostained on a DAKO Cytomation autostainer (DAKO, Glostrup, Denmark), using monoclonal mouse anti-human antibody against MGMT (clone MT3.1, MAB16200 EMD Millipore TM , Billerica, MA, USA).

    Techniques: Expressing

    Univariate and multivariate Cox hazard regression analysis for PFS and OS. *: statistically significant.

    Journal: Bioengineering

    Article Title: Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

    doi: 10.3390/bioengineering6010011

    Figure Lengend Snippet: Univariate and multivariate Cox hazard regression analysis for PFS and OS. *: statistically significant.

    Article Snippet: After blocking of endogenous peroxidase with 3% H 2 O 2 , the sections were pre-treated in an oven with EnVision Flex TRS buffer and immunostained on a DAKO Cytomation autostainer (DAKO, Glostrup, Denmark), using monoclonal mouse anti-human antibody against MGMT (clone MT3.1, MAB16200 EMD Millipore TM , Billerica, MA, USA).

    Techniques: Expressing